Categories Earnings, Health Care

Neos Therapeutics (NASDAQ: NEOS): Q4 2019 Earnings Snapshot

— Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share expected.

— Total product revenue grew by 9.1% to $16.8 million versus $20.57 million expected.

Earnings Update by AlphaStreet

— The bottom line reflected the evolution of the commercial strategy and the company’s focus on both operational productivity and expense management.

— The company reported growth in net product sales and net revenue per pack for its two core commercial attention deficit hyperactivity disorder (ADHD) products, Adzenys XR-ODT and Cotempla XR-ODT.

— During the fourth quarter of 2019, the company substantially expanded the number of participating pharmacies in the Neos RxConnect network to about 500 pharmacies, including one regional pharmacy chain, as of December 31, 2019.

— Neos recently agreed with a third-party to commercialize Neos’ ADHD portfolio in Puerto Rico. The commercial launch is anticipated to occur in the second quarter of 2020.

— The company achieved top-line results from the NT0502 Phase 1 pilot pharmacokinetic study and plans to initiate an ascending dose study in the second half of the year. This underserves patients struggling with chronic sialorrhea, otherwise known as excessive drooling, across numerous debilitating CNS disorders.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top